My Impressions and Response to the Trial to Assess Chelation Therapy Completed by the NIH

Chelation Therapy is a wonderfully effective, safe, comprehensive program that can benefit people with chronic degenerative diseases. People with conditions like heart disease, diabetes, arthritis, lack of energy and problems of aging can experience a resurgence of energy and life quality. This program is not new. It has been studied and offered to patients by many progressive physicians to hundreds of thousands of thankful people world wide for over 60 years. Patients who receive chelation therapy experience their quality of life improve first hand. The doctors who provide individualized programs enjoy their observations of their patients' improvements.

It makes our day that we are no longer alone in these observations; the United States government via the National Institutes of Health (NIH) funded a study on chelation therapy. The study called TACT, Trial to Assess Chelation Therapy, started in 2003. The results were just announced at the American Heart Association's meeting November 4, 2012. The results were positive.

People in this trial who received Chelation Therapy had decreased hospitalizations for angina, compared to the control group. There were fewer deaths from heart attacks and strokes for the patients receiving chelation therapy. The chelation patients also needed less bypass surgeries and angioplasties; the findings were especially positive for patients who also suffered from diabetes. Chelation Therapy reduced cardiac events by 18% and by 39% for diabetic patients. The total reduction in cardiac events was statistically significant. Physicians conducting the study included university cardiologists and experienced chelation physicians.

Keep in mind all study participants had a previous heart problem before beginning the trial, 83% had either bypass surgeries, angioplasty with or without stents. The majority of participants had high blood pressure and 73% had been prescribed cholesterol lowering statin drugs. One thousand seven hundred people participated in the study. An additional finding was the unquestionable safety of Chelation Therapy.

Considering the decrease need for angioplasty and bypass surgery — would you be surprised to see the cardiology and cardiovascular surgeons less than enthusiastic about the study results?

Those of us who have been trained to provide Chelation Therapy for the benefit of our patients have known for many years the wide range of improvement possible for our patients. Through thick and thin our care has been without support in the main from mainstream medicos so we welcome scientific evidence from a large clinical trial confirming some of the many benefits we have observed in our patients.

Truth be told, however, if the study was not positive I would have continued to provide Chelation Therapy to my patient family and continued my own Chelation program. I know the benefits of providing Chelation Therapy after forty years of providing this care in clinical practice. I see PVD, heart disease, high blood pressure, and diabetes abate all the time. Some of our diabetic patients no longer require insulin injections.

Although I have been providing Chelation Therapy for over 35 years I chose not to be one of the participating physicians. I understand the significance the majority of the medical profession places on the double blind study protocol. I was uncomfortable in treating any patient with a placebo. I do want to thank all the chelation physicians who did participate. You are to be commended and we owe you a debt of gratitude. I also want to thank all of the patient participants, we owe them a debt of gratitude as well. Kudos to all who continue the good fight for what is right.

Best in health,

Conrad G. Maulfair, Jr DO